In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Pyxis Oncology, with a price target of $6.00.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence
Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
According to TipRanks, Slutsky is a top 100 analyst with an average return of 43.5% and a 52.22% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Palvella Therapeutics, and Enliven Therapeutics.
In addition to LifeSci Capital, Pyxis Oncology also received a Buy from Wedbush’s Robert Driscoll in a report issued on May 18. However, on May 14, William Blair reiterated a Hold rating on Pyxis Oncology (NASDAQ: PYXS).
Based on Pyxis Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $23.27 million. In comparison, last year the company had a GAAP net loss of $21.16 million
